Reviva Pharmaceuticals announces $10M public offering of stock and warrants

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.
Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.
Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.
Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-03-18).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Value: 7.0% of the aggregate gross proceeds
Effective: 2026-03-18

Exact text from the filing

the Company entered into a placement agency agreement (the “Placement Agency Agreement”), dated March 18, 2026, with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at $10.0 million (effective 2026-03-18).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: $10.0 million
Effective: 2026-03-18

Exact text from the filing

On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-009063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.